Access Program Information
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of
treatment for hematological abnormalities. Poor graft function, occurs when there poor donor
engraftment. A second infusion of unselected donor hematopoietic stem cells (HSC) can result
in improvement, but can potentially increase the incidence of graft versus host disease.
Cluster of differentiation 34+ (CD34+) selected stem cells depleted of T-cells is an
attractive alternative for treatment of poor graft function as it may be associated with
less Graft versus Host Disease (GVHD) and enhanced count recovery. The investigators are
using the Miltenyi CliniMACS device and CD34 cell selection reagents for the preparation of
allogeneic hematopoietic progenitor cell (HPC) transplants for patients who have had prior
stem cell transplants and require a stem cell “boost” from the original donor.